오믹스 기반 임상시험 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global omics-based clinical trials market size is expected to reach USD 77.39 Billion in 2034 from USD 37.57 Billion in 2025, growing at a CAGR of 8.36 during 2026-2034.This market is expanding rapidly due to increasing adoption of precision medicine and advanced genomic research in healthcare. Omics-based clinical trials use genomics, proteomics, metabolomics, and related technologies to develop personalized treatment approaches and improve drug development efficiency. Rising prevalence of chronic diseases and growing demand for targeted therapies are significantly driving market growth. Technological advancements in sequencing technologies and bioinformatics are also accelerating clinical research activities globally.

Increasing pharmaceutical research investments and rising focus on biomarker-driven therapies are major factors supporting market expansion. Healthcare organizations and biotechnology companies are using omics technologies to improve patient stratification, treatment response analysis, and clinical trial success rates. Growing collaboration between research institutions and pharmaceutical companies is further strengthening industry development. In addition, supportive regulatory frameworks and increasing funding for precision medicine initiatives are positively influencing market adoption worldwide.

Future prospects for the omics-based clinical trials market remain highly favorable due to continuous advancements in artificial intelligence and data analytics. Integration of machine learning with genomic data analysis is expected to improve trial efficiency and accelerate drug discovery processes. Emerging economies are projected to witness increased research activities due to improving healthcare infrastructure and biotechnology investments. As personalized healthcare and targeted therapeutics continue evolving, the market is anticipated to experience sustained global growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional Studies
• Observational Studies
• Expanded Access Studies

By Indication

• Autoimmune / Inflammation
• Pain Management
• Oncology
• CNS Conditions
• Diabetes
• Obesity
• Cardiovascular
• Others

COMPANIES PROFILED

• Parexel International (MA) Corporation, Thermo Fisher Scientific Inc., Charles River Laboratories, ICON plc, SGS Societe Generale de Surveillance SA, Eli Lilly and Company, Pfizer Inc., Laboratory Corporation of America, Novo Nordisk A/S, Rebus Biosystems, Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: BY PHASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Phase
• 4.2. Phase I Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Phase II Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Phase III Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Phase IV Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: BY STUDY DESIGN 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Study Design
• 5.2. Interventional Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Observational Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Expanded Access Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Autoimmune / Inflammation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pain Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. CNS Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Obesity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Phase
  • 7.2.2 By Study Design
  • 7.2.3 By Indication
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Phase
  • 7.3.2 By Study Design
  • 7.3.3 By Indication
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Phase
  • 7.4.2 By Study Design
  • 7.4.3 By Indication
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Phase
  • 7.5.2 By Study Design
  • 7.5.3 By Indication
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Phase
  • 7.6.2 By Study Design
  • 7.6.3 By Indication
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OMICS-BASED CLINICAL TRIALS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Parexel International (MA) Corporation
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 Charles River Laboratories
  • 9.2.4 ICON Plc
  • 9.2.5 SGS Societe Generale De Surveillance SA
  • 9.2.6 Eli Lilly And Company
  • 9.2.7 Pfizer Inc
  • 9.2.8 Laboratory Corporation Of America
  • 9.2.9 Novo Nordisk A/S
  • 9.2.10 Rebus BiosystemsInc